Impelling Times for Tissue Section Proteomics in Cancer
Nature Cell and Science · 2024
DOI: 10.61474/ncs.2023.00036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Cell and Science, 2024. Verfasst von Atif A. Ahmed und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
[No abstract available in the source PDF. First paragraph follows.] ncs.2023.00036. Introduction Cancer drug development in the modern era focuses on identifying inhibitors of gene products directly involved in the pathogenesis of cancers. These new molecularly targeted drugs are more selective and specific for cancer types that express the variant gene product. Therapy-relevant targets have traditionally been identified through molecular testing methodologies such as polymerase chain reaction, fluorescent in situ hybridization (FISH), and massive parallel sequencing or next-generation sequencing (NGS) methods. The latter can serve as screening or definitive tests, high lighting the presence of targeted gene variants and helping in selecting the most appropriate agents for clinical use or further research.
Zitieren
APA
Ahmed, A. A., & Ouban, A. (2024). Impelling Times for Tissue Section Proteomics in Cancer. Nature Cell and Science. https://doi.org/10.61474/ncs.2023.00036
Vancouver
Ahmed AA, Ouban A. Impelling Times for Tissue Section Proteomics in Cancer. Nature Cell and Science. 2024. doi:10.61474/ncs.2023.00036
BibTeX
@article{Ahmed2024,
author = {Ahmed, Atif A. and Ouban, Abderrahman},
title = {Impelling Times for Tissue Section Proteomics in Cancer},
journal = {Nature Cell and Science},
year = {2024},
doi = {10.61474/ncs.2023.00036}
}
EUVIMED